Top 50 Big Pharma Companies Dealmaking Activity Discussed in New CurrentPartnering Study Available at

Share Article

New research study “Top 50 Big Pharma Partnering and M&A Deal Trends” worked out by CurrentPartnering is now available at

TD The Market Publishers Ltd

What is really granted by the agreement to the cooperating company? What exclusive privilege is granted? What is the deal’s payment structure? How are payments and sales audited? What is the term of a deal? How are the key agreement terms defined? How are intellectual property rights handled and owned? Who is responsible for commercialisation? Who is in charge of development, manufacture, and supply? How is publication and confidentiality managed? How are disputes being resolved? Under what conditions can the deal come to an end? What occurs in case ownership changes? What sub-contracting and sub-licensing provisions have been agreed? Upon which boilerplate clauses does the firm insist? Which boilerplate clauses seem to differ from deal type to deal type or partner to partner? Which jurisdiction is the company insistent on for agreement law? These and many more other burning questions are answered in the report.

Answers for these and other important questions are given in new research study “Top 50 Big Pharma Partnering and M&A Deal Trends” worked out by CurrentPartnering is now available at

Report Details:

Title: Top 50 Big Pharma Partnering and M&A Deal Trends
Published: October, 2014
Pages: 816
Price: US$ 3,295.00

The research report provides a refined understanding and unprecedented access to the dealmaking interests and activities of the top 50 big pharma companies worldwide, allowing for the effective evaluation and selection of partners of choice, on the basis of the most recent knowledge of a company’s partnering. The research study is an indispensible tool for those seeking to conclude a successful contact with the proper big pharma partners efficiently and effectively.

Report Benefits:

  •     Detailed partnering activity profiles for each of the top 50 big pharma companies
  •     More than 300 charts demonstrating a given company's dealmaking activity during 2009-2014, helping to quickly identify prospective partners.
  •     Partnering therapy focus revealed.
  •     Partnering activities since 2009 – the number of deals closed per annum.
  •     Partnering activity during 2009-2014.

o    Complete listing of partnering deals 2009-2014.
o    Activity by deal type.
o    Activity by industry sector.
o    Activity by phase of development.
o    Activity by technology type.
o    Activity by therapeutic area.

  •     Unrivalled access to more than 3,000 partnering deals, alongside contract documentation if available.
  •     Deep insights into the terms that are included in a partnering agreement, in tandem with real-world clause examples, through contract documents.
  •     Gain an understanding of the key deal terms the firm has agreed upon in previous deals.
  •     Undertake due diligence to assess the appropriateness of your proposed deal terms for partner firms.

More new studies by the publisher can be found at CurrentPartnering page.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Natalie Aster
Follow >
Like >
Follow us on